Apitope Presenting At The Peptide Conference On 30 March 2010
3/30/2010 4:09:18 PM
Bristol, UK / Hasselt, Belgium – 29 March 2010: Apitope International N.V., the autoimmune peptide therapy company, announced today that Dr. Keith Martin, CEO, will give an overview of the Company’s business at ‘The Peptide Conference’. The presentation will be at The Wellcome Trust Conference Centre, Cambridge, UK at 4pm (BST) on Tuesday, 30th March 2010.
The presentation will provide an insight into how Apitope designs and develops therapeutic peptides for revolutionary treatment of autoimmune diseases and allergies.
The conference will feature leading researchers and experts from the various fields of peptide therapeutics development, presenting the latest scientific and technological knowledge in these rapidly advancing areas of life sciences. The applications of peptide chemistry from synthesis through purification and analytics,bioactivity testing in biotechnology, biomedical and other applications from analytical to industrial scales will be presented.
Apitope International NV is a biopharmaceutical company with headquarters in Hasselt, Belgium and a subsidiary in Bristol, England. The Company is developing novel products to revolutionize the diagnosis and treatment of chronic autoimmune and allergic disorders. Apitope’s therapeutic peptide technology platform is based on established scientific evidence showing that soluble, synthetic peptides can reinstate tolerance and selectively attenuate pathological immune responses. The ApitopesTM (Antigen Processing Independent epiTOPES) inhibit the immune system's harmful attack on the body while preserving normal immune responses to harmful antigens, such as infections. Apitope’s portfolio includes novel peptide therapies for MS as well as other autoimmune diseases and common allergies. Apitope is also developing novel diagnostic products for the early detection of autoimmune diseases such as MS and rheumatoid arthritis (RA). Apitope is backed by LRM; Vesalius Biocapital; Fast Forward, VINNOF; Hasselt University; The Wellcome Trust; the Daniels family, Wyvern Seedcorn Fund and the University of Bristol.
comments powered by